bluuebunny/crossref_metadata_2025_split huggingface dataset:
Identification of adenylate cyclase 2 methylation in bladder cancer with implications for prognosis and immunosuppressive microenvironment
Authors: Yang Jianfeng , Xu Jin , Gao Qian , Wu Fan , Han Wei , Yu Chao , Shi Youyang , Qiu Yunhua , Chen Yuanbiao , Zhou Xiqiu 
Published: October 2022

BackgroundThe incidence and mortality of bladder cancer (BCa) are increasing, while the existing diagnostic methods have limitations. Therefore, for early detection and response prediction, it is crucial to improve the prognosis and treatment strategies. However, with existing diagnostic methods, detecting BCa in the early stage is challenging. Hence, novel biomarkers are urgently needed to improve early diagnosis and treatment efficiency.MethodsThe gene expression profile and gene methylation profile dataset were downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs), differentially methylated genes (DMGs), and methylation-regulated differentially expressed genes (MeDEGs) were gradually identified. A cancer genome map was obtained using online gene expression profile interaction analysis, and survival implications were produced using Kaplan-Meier survival analysis. GSEA was employed to predict the marker pathways where DEGs were significantly involved. The study used bisulfite PCR amplification combined with bisulfite amplicon sequencing (BSAS) to screen for methylation analysis of multiple candidate regions of the adenylate cyclase 2 (ADCY2) based on the sequence design of specific gene regions and CpG islands.ResultsIn this study, DEGs and DMGs with significantly up- or down-regulated expression were selected. The intersection method was used to screen the MeDEGs. The interaction network group in STRING was then visualized using Cytoscape, and the PPI network was constructed to identify the key genes. The key genes were then analyzed using functional enrichment. To compare the relationship between key genes and the prognosis of BCa patients, we further investigated ADCY2 and found that ADCY2 can be a potential clinical biomarker in BCa prognosis and immunotherapy response prediction. In human BCa 5637 and MGH1 cells, we developed and verified the effectiveness of ADCY2 primers using BSAS technology. The findings revealed that the expression of ADCY2 is highly regulated by the methylation of the promoter regions.ConclusionThis study revealed that increased expression of ADCY2 was significantly correlated with increased tumor heterogeneity, predicting worse survival and immunotherapy response in BCa patients.
The potential of biology-guided radiation therapy in thoracic cancer: A preliminary treatment planning study
Authors: Seyedin Steven N. , Bassalow Rostem , Mawlawi Osama R. , Turner Lehendrick M. , Patel Roshal R. , Mazin Samuel R. , Oderinde Oluwaseyi M. , Voronenko Yevgen , Wages Cody A. , Olcott Peter D. , Chang Joe Y. , Balter Peter A. , Welsh James W. 
Published: October 2022

PurposeWe investigated the feasibility of biology-guided radiotherapy (BgRT), a technique that utilizes real-time positron emission imaging to minimize tumor motion uncertainties, to spare nearby organs at risk.MethodsVolumetric modulated arc therapy (VMAT), intensity-modulated proton (IMPT) therapy, and BgRT plans were created for a paratracheal node recurrence (case 1; 60 Gy in 10 fractions) and a primary peripheral left upper lobe adenocarcinoma (case 2; 50 Gy in four fractions).ResultsFor case 1, BgRT produced lower bronchus V40 values compared to VMAT and IMPT. For case 2, total lung V20 was lower in the BgRT case compared to VMAT and IMPT.ConclusionsBgRT has the potential to reduce the radiation dose to proximal critical structures but requires further detailed investigation.
The incidence risk of breast and gynecological cancer by antidepressant use: A systematic review and dose–response meta-analysis of epidemiological studies involving 160,727 patients
Authors: Zhuang Yanjia , Pang Xiaogang , Qi Yuchen , Zhang Tianshu , Cao Guimao , Xue Heming , Xu Yifan , Xie Shuoxin , Liu Yifan , Wang Yinuo , Li Yunxiao , Xiong Ying , Li Yuanyuan , Shen Hui 
Published: October 2022

Background and objectiveAntidepressants are widely prescribed to treat depression and anxiety disorders that may become chronic conditions among women. Epidemiological studies have yielded inconsistent results on the correlation between antidepressant use and the incidence risk of female breast and gynecological cancer, along with uncertain dose–response relationship. Therefore, we performed a systematic review and dose–response meta-analysis to investigate the association.MethodsWeb of Science, Embase, PubMed, The Cochrane Library, and PsycINFO were systematically searched in January 2022, with no language limits. Random-effect models were used to calculate pooled effect sizes and 95% confidence intervals between studies. Linear and non-linear dose–response analyses were performed to evaluate the dose or duration of antidepressant use affecting the incidence risk of female breast and gynecological cancer. Further subgroup analyses were systematically performed by stratifying almost all study characteristics and important potential confounders, in order to further clarify and validate the important potential hypotheses regarding the biological mechanism underlying this association.ResultsBased on a systematic literature search, 34 eligible studies (27 case–control studies and 7 cohort studies) involving 160,727 female breast and gynecological cancer patients found that antidepressant use did not increase the incidence risk of female breast and gynecological cancer (pooled OR: 1.01; 95% CI: 0.97, 1.04, I² = 71.5%, p &lt; 0.001), and even decreased the incidence risk of ovarian cancer (pooled OR: 0.91; 95% CI: 0.83, 1, I² = 17.4%, p = 0.293). There were a non-linear dose–response relationship (p non-linearity &lt; 0.05) between the duration of antidepressant use and incidence risk of female breast cancer, and an inverse linear dose–response relationship between antidepressant use and the incidence risk of gynecological cancer, specifically with an increase of cumulative defined daily dose or duration to a high level, like 25,550 doses (OR: 0.91, 95% CI: 0.85–0.98, p linearity &lt; 0.05) or 4,380 days (OR: 0.82; 95% CI: 0.7, 0.96, p linearity &lt; 0.05), compared to never antidepressant users.ConclusionThis systematic review and dose–response meta-analysis found that antidepressant use did not increase the incidence risk of female breast and gynecological cancer and even decreased the incidence risk of ovarian cancer, along with a non-linear or linear dose–response relationship.Systematic Review RegistrationPROSPERO https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=313364, identifier CRD42022313364.
Modified robotic-assisted laparoscopic pyeloplasty in children for ureteropelvic junction obstruction with long proximal ureteral stricture: The “double-flap” technique
Authors: Han Ce , Ma Lifei , Li Pin , Wang Jia’nan , Zhou Xiaoguang , Tao Tian , Cao Hualin , Tao Yuandong , Yang Yunjie , Zhao Yang , Zhu Weiwei , Guo Tao , Lyu Xuexue , Zhuo Ran , Zhou Huixia 
Published: October 2022

ObjectiveThe objective of this study is to introduce a novel technique of robotic-assisted laparoscopic pyeloplasty (RALP) for ureteropelvic junction obstruction (UPJO) with long proximal ureteral stricture in children.Materials and methodsClinical information on patients who underwent a modified RALP between July 2018 and May 2019 in our center was collected retrospectively. Our surgical modifications mainly include “double-flap” tailoring of the renal pelvis and anastomosis of spatulate ureter with the double-flap. Demographic, perioperative, postoperative, and follow-up information was recorded in detail.ResultsA total of 13 patients were included in the study. All the patients underwent a modified RALP without conversion to open surgery. They were followed up with a median time of 36 months. The anteroposterior diameter of the renal pelvis was 1.19 ± 0.21 at 6 months after the surgery, which was significantly lower than that on admission (3.93 ± 0.79). The split renal function of the children was also significantly improved from 0.37 ± 0.05) to 0.46 ± 0.02 at 6 months after surgery (p &lt; 0.05). The diuretic renography revealed that all the patients have a T1/2 time less than 20 min postoperatively. The children were in good condition during the follow-up period.ConclusionsModified RALP is an effective surgical treatment for children with UPJO with long proximal ureteral stricture. The success rate of this modification has been preliminarily confirmed.
Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis
Authors: Cherian Jerin Jose , Eerike Madhavi , Bagepally Bhavani Shankara , Das Saibal , Panda Samiran 
Published: October 2022

Objective: This review was performed to compare the efficacy and safety among hospitalized patients with COVID-19 who received baricitinib and those who received tocilizumab independently with placebo or the standard of care (SOC).Methods: Relevant databases were searched for randomized controlled trials which evaluated the effect of baricitinib or tocilizumab as compared to placebo or the SOC in hospitalized patients with COVID-19. The primary endpoint was the comparison of the 28-day mortality. Risk ratios (RR) and mean differences were compared and pooled for dichotomous and continuous variables, respectively. A two-staged exploratory network meta-analysis using a multivariate meta-analysis was also performed. All analyses were performed in Stata version 16.0. The GRADE approach was used to assess the quality of the generated evidence (PROSPERO ID: CRD42022323363).Results: Treatment with baricitinib [RR, 0.69 (95% CI, 0.50–0.94), p = 0.02, i2 = 64.86%] but not with tocilizumab [RR, 0.87 (95% CI, 0.71–1.07), p = 0.19, i2 = 24.41%] led to a significant improvement in the 28-day mortality as compared to that with the SOC. Treatment with baricitinib or tocilizumab, both independently led to a significant reduction in the duration of hospitalization [baricitinib: mean difference, −1.13 days (95% CI, −1.51 to −0.76), p &lt; 0.001, i2 = 0.00%; tocilizumab: mean difference, −2.80 days (95% CI, −4.17 to −1.43), p &lt; 0.001, i2 = 55.47%] and a significant improvement in the proportion of patients recovering clinically by day 28 [baricitinib: RR, 1.24 (95% CI, 1.03–1.48), p = 0.02, i2 = 27.20%; tocilizumab: RR, 1.41 (95% CI, 1.12–1.78), p &lt; 0.001, i2 = 34.59%] as compared to those with the SOC. From the safety point of view, both these drugs showed similar results. There were fewer patients who experienced any serious adverse event following treatment with barictinib and tocilizumab as compared to those following treatment with the SOC [baricitinib: RR, 0.76 (95% CI, 0.62–0.92), p = 0.01, i2 = 12.63%; tocilizumab: RR, 0.85 (95% CI, 0.72–1.01), p = 0.07, i2 = 0.00%].Conclusion: As baricitinib and tocilizumab are recommended interchangeably by various guidelines for the management of COVID-19, considering the better 28-day mortality data and other comparable efficacy and safety outcomes, baricitinib may be favored over tocilizumab considering its ease of administration, shorter half-life, and lower cost of treatment.
Efficacy evaluation of Buyang Huanwu Decoction in the treatment of ischemic stroke in the recovery period: A systematic review of randomized controlled trials
Authors: Wang Raoqiong , Ren Junhao , Li Shuangyang , Bai Xue , Guo Wubin , Yang Sijin , Wu Qibiao , Zhang Wei 
Published: October 2022

Background and purpose: Buyang Huanwu decoction (BYHWD) is widely used in the treatment of ischemic stroke in the recovery period, and many clinical trials have been reported, but its clinical efficacy and safety have not been fully evaluated. In this study, we conducted a systematic review and meta-analysis to evaluate the clinical efficacy and safety of BYHWD in the recovery period.Materials and methods: Eight databases, including CNKI, Wanfang Database, VIP Database, China Biomedical Literature Database, PubMed, Cochrane Library, EMBASE, and Web of Science, were searched from the establishment of the database to 13 April 2022. We selected all eligible randomized controlled trials of BYHWD in the treatment of ischemic stroke during the recovery period. Systematic review and meta-analysis were conducted in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines. The National Institutes of Health Stroke Score (NIHSS) was the primary outcome, and the Chinese Stroke Scale (CSS), activities of daily living (ADL), and adverse drug reaction (ADR) were the secondary outcomes.Results: A total of 39 randomized controlled trials were included, and 3,683 patients in the recovery period of ischemic stroke were recruited. Compared with conventional treatment alone, BYHWD combined with conventional treatment significantly decreased the NIHSS score (MD = -1.44, 95% CI: 1.75, -1.12, p &lt; 0.00001), the CSS score (MD = -1.18, 95% CI: 2.02, -0.34, p = 0.006), improved the ADL (MD = 4.33, 95% CI: 3.06, 5.61, p &lt; 0.00001), and did not increase the adverse reactions of patients (OR = 0.88, 95% CI: 0.48, 1.61, p = 0.67).Conclusion: BYHWD is an effective and safe therapy for the recovery of ischemic stroke. To further determine the efficacy and safety of BYHWD in the treatment of ischemic stroke in the recovery period, more high-quality, multicenter, and prospective RCTs are needed.
Ion chamber magnetic field correction factors measured via microDiamond cross-calibration from a conventional linac to MRI-linac
Authors: Begg Jarrad , Jelen Urszula , Keall Paul , Liney Gary , Holloway Lois 
Published: October 2022

Magnetic field correction factors are required for performing reference dosimetry on Magnetic Resonance Imaging Linear accelerators (MRI-linacs). Methods for measuring magnetic field correction factors usually require specialized equipment and expertise. Our work investigated the use of a microDiamond detector to cross-calibrate an ion chamber between a conventional linac and MRI-linac as a method to measure ion chamber magnetic field correction factors for the MRI-linac. Ratios of the microDiamond and ion chamber were measured on a conventional linac, parallel MRI-linac at 0 T, parallel MRI-linac at 1 T and perpendicular MRI-linac at 1.5 T. The beam quality dependence of the microDiamond was investigated by comparing the measurements on the conventional linac and parallel MRI-linac at 0 T. The magnetic field dependence of the microDiamond was investigated comparing the measurements on a parallel MRI-linac at 0 and 1 T. The ion chamber magnetic field correction factors were calculated by comparing the conventional linac and parallel MRI-linac at 1 T and the conventional linac and perpendicular MRI-linac at 1.5 T for the parallel and perpendicular factors respectively. The FC65-G and PTW30013 ion chambers were investigated. For a parallel MRI-linac, with a beam quality of TPR20,10 = 0.632, we measured magnetic field correction factors of 0.988 ± 0.016 (k = 2) and 0.987 ± 0.016 (k = 2) for a FC65-G and PTW30013 respectively, where k is the coverage factor. For a perpendicular MRI-linac, with a beam quality of TPR20,10 = 0.701, we measured magnetic field correction factors of 0.995 ± 0.020 (k = 2) and 0.983 ± 0.020 (k = 2) for a FC65-G and PTW30013 respectively. The results showed agreement with previously published work which used different approaches. Our work demonstrates the use of a microDiamond to calculate the ion chamber magnetic field correction factor using measurements on a conventional linac and MRI-linac. The high level of uncertainty in our results means the method at present can only be used for validation of magnetic field correction factors.
Training at moderate altitude improves submaximal but not maximal performance-related parameters in elite rowers
Authors: Cerda-Kohler Hugo , Haichelis Danni , Reuquén Patricia , Miarka Bianca , Homer Mark , Zapata-Gómez Daniel , Aedo-Muñoz Esteban 
Published: October 2022

Maximal oxygen consumption (V̇O2max), physiological thresholds, and hemoglobin mass are strong predictors of endurance performance. High values of V̇O2max, maximal aerobic power (MAP), and power output at anaerobic thresholds are key variables in elite rowers. Endurance athletes often use altitude training as a strategy to improve performance. However, no clear evidence exists that training at natural altitude enhances sea-level performance in elite rowers. This study aimed to evaluate the effect of altitude training on rowing-performance parameters at sea level. The study was conducted on eleven rowers (Six females, five males) from the Chilean National Team during a 3-week moderate altitude training (∼2,900 m. a.s.l.) under the live high-train high (LHTH) model. It included a rowing ergometer maximal incremental test and blood analysis (pre and post-altitude). Gas exchange analysis was performed to measure V̇O2max, ventilatory thresholds (VTs) and rowing economy/efficiency (ECR/GE%). LHTL training improves performance-related variables at sea level (V̇Emax: 3.3% (95% CI, 1.2–5.5); hemoglobin concentration ([Hb]): 4.3% (95% CI, 1.7–6.9); hematocrit (%): 4.5% (95% CI, 0.9–8.2); RBC (red blood cells) count: 5.3% (95% CI, 2.3–8.2); power at VT2: 6.9% (95% CI, 1.7–12.1), V̇EVT2: 6.4% (95% CI, 0.4–12.4); power at VT1: 7.3% (95% CI, 1.3–13.3), V̇EVT1: 8.7% (95% CI, 1.6–15.8)) and economy/efficiency-related variables (ECRVT2: 5.3% (95% CI, −0.6 to −10.0); GE(%): 5.8% (95% CI, 0.8–10.7)). The LHTH training decreased breathing economy at MAP (−2.8% (95% CI, 0.1–5.6)), pVT2 (−9.3% (95% CI, −5.9 to −12.7)), and pVT1 (−9.3% (95% CI, −4.1 to −14.4)). Non-significant changes were found for V̇O2max and MAP. This study describes the effects of a 3-week moderate altitude (LHTH training) on performance and economy/efficiency-related variables in elite rowers, suggesting that it is an excellent option to induce positive adaptations related to endurance performance.
Crab barrel syndrome: Looking through the lens of type A and type B personality theory and social comparison process
Authors: Uzum Burcu , Ozdemir Yasemin , Kose Semra , Ozkan Osman Seray , Seneldir Okan 
Published: October 2022

IntroductionThere are epistemological studies about the main concept, Crab Syndrome. In this context, the study aims to reveal the antecedents of the Crab Syndrome by evaluating the theoretical background of the Crab Barrel Syndrome within the framework of Social Comparison Theory. The main purpose of this study is to identify the precursors of crab barrel syndrome. In line with this main purpose, the study also aims to reveal the relationship between crab barrel syndrome behaviors and type A versus type B personalities, along with the effect of social comparison behaviors. Type A personality represents the personalities of individuals who are stressed, ambitious, competitive, and quickly take action for their aims. Type B, on the other hand, presents the personality types of individuals who are calm, away from competition, and perform their actions slowly.MethodIt is designed quantitatively, employing scales to quantify type A and type B personalities, social comparison, and crab barrel syndrome. Hypotheses are tested using structural equation modeling.Result/discussionIt is found that there is a positive relation between the type A personality and the crab barrel syndrome, and a negative one between the syndrome and high self-esteem. The findings suggest that by social comparison, type A and type B personality are precursors of crab barrel syndrome. In the study, the theoretical background of the Crab Syndrome was evaluated within the scope of Social Comparison Theory. In this context, examining the relationship between different organizational behavior theories and crab syndrome is important for other studies.
Central adiposity increases the odds for plasma folate deficiency among Chinese women of reproductive age
Authors: Zhang Jinjuan , Du Yushan , Che Xiaoyu , Xia Shuangbo , Zhang Le , Liu Jufen 
Published: October 2022

ObjectiveTo explore the association between adiposity and plasma folate deficiency odds among women of reproductive age in China.MethodsA cross-sectional survey on nutritional status among women of reproductive aged 18–30 years in 2005–2006 in China was conducted. General adiposity was defined as body mass index (BMI) ≥24 kg/m2, and central adiposity was defined as waist circumference &gt;80 cm. A plasma folate concentration &lt;10.5 nmol/L (measured through microbiological assay) was defined as plasma folate deficiency. Odds ratios (ORs) and 95% confidence intervals (CIs) for plasma folate deficiency were calculated using a logistic regression model, with adjustment for potential confounders.ResultsA total of 3,076 women of reproductive age were included in the final analysis. Compared to women with normal BMI and WC, women with both general and central adiposity had the highest odds for plasma folate deficiency (OR = 3.107, 95% CI: 1.819–5.307). Women with exclusively central adiposity had excess odds for plasma folate deficiency (WC &gt; 80 cm, BMI &lt;24 kg/m2; OR = 2.448, 95% CI: 1.144–5.241), which was higher than women with exclusively general adiposity (BMI ≥ 24 kg/m2, WC ≤ 80 cm; OR = 1.709, 95% CI: 1.259–2.319). The combined use of BMI and WC can detect more women (11.7%) at higher plasma folate deficiency odds than either used alone.ConclusionsWomen with central adiposity in normal weight have higher odds for plasma folate deficiency than those with general obesity only. Early screening for central adiposity among women of reproductive age would be meaningful to prevent folate deficiency and improve life-cycle health.
Protein intake from different sources and cognitive decline over 9 years in community-dwelling older adults
Authors: Gao Rongtao , Yang Zhan , Yan Wenju , Du Weiping , Zhou Yuan , Zhu Feng 
Published: October 2022

ObjectivesTo examine the association of protein intake from different sources with cognitive decline.MethodsOur analysis included 3,083 participants aged 55–93 years from the China Health and Nutrition Survey. Cognition was assessed in 1997, 2000, 2004, 2006, and 2015. Diet intake was assessed using weighing methods in combination with 24-h dietary recalls for three consecutive days at each survey.ResultsParticipants consumed 13.94% of energy intake from total protein, with 11.47 and 2.47% from plant and animal sources, respectively. During a follow-up of 9 years, participants in quintile 5 of plant protein intake (% energy) had a higher risk [odds ratio (95% CI): 3.03 (1.22–7.53)] of cognitive decline compared with those in quintile 1. Higher animal protein intake (% total protein) was associated with a lower risk of cognitive decline [odds ratio (95% CI) for quintile 5 vs. quintile 1: 0.22 (0.07–0.71)]. Grains (plant source) protein intake was inversely but fish/shrimp and poultry (animal source) protein intake were positively associated with change in cognitive Z-score.ConclusionIncreasing animal protein consumption in a population with plant dominant diets may help to prevent cognitive decline.